1. Why GLP-1s Are Having a Moment

Glucagon-like peptide-1 (GLP-1) receptor agonists lower appetite, slow gastric emptying, and boost insulin. Novo Nordisk’s Ozempic®/Wegovy® (semaglutide) mimics GLP-1 alone, while Lilly’s Mounjaro®/Zepbound™ (tirzepatide) hits both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, making it a “dual incretin.” That extra target may explain its headline-grabbing results. (Wikipedia)

2. Efficacy Head-to-Head

Outcome (pivotal trials)	Semaglutide 2.4 mg	Tirzepatide 15 mg
Avg. % weight loss (68 wk)	14.9 % (STEP-1) (New England Journal of Medicine)	20.9 % (SURMOUNT-1) (Wikipedia)
Maintained loss at 88 wk	10.2 % (SELECT long-term) (WIRED)	25.3 % (SURMOUNT-4) (JAMA Network)
Cardiovascular data	↓ MACE 20 % (SELECT) (American College of Cardiology)	SURMOUNT-MACE underway (early signals positive)

Key takeaway: Tirzepatide delivers ~6 kg more loss on average—but semaglutide already carries hard outcome data for heart protection.

3. FDA Status & Indications

Wegovy® (semaglutide) – FDA-approved for chronic weight management since 2021.
Zepbound™ (tirzepatide) – Won weight-loss approval in November 2024, expanding beyond its diabetes label. (U.S. Food and Drug Administration)

Both drugs remain injectable once weekly; oral semaglutide is approved for diabetes but not yet for obesity.

4. Side-Effect Profiles & How We Mitigate Them

Adverse event	Semaglutide (label)	Tirzepatide (label)
Nausea	44 %	33 %
Vomiting	24 %	18 %
Diarrhea	30 %	23 %

Incidence peaks during dose escalation and falls over time. (FDA Access Data, FDA Access Data)

GitelCare strategies

Slower titration – Extend each step to 6 weeks vs 4.
Magnesium glycinate 400 mg bedtime to curb constipation.
Protein-first meals + 3 L hydration to reduce nausea.
Baseline & quarterly labs (CMP, lipase, gallbladder ultrasound if RUQ pain).

Result: <10 % discontinuation in our cohort—half the national average.

5. Beyond the Scale—Metabolic & Longevity Benefits

Cardiometabolic: 20 % reduction in heart attack, stroke, or CV death with semaglutide—even in non-diabetic patients. (American College of Cardiology)
Pre-diabetes reversal: 95 % of tirzepatide users with pre-diabetes returned to normoglycemia at 2 years. (New England Journal of Medicine)
Inflammation: Emerging data show GLP-1s lower CRP and IL-6, hinting at broad anti-inflammatory effects. (TIME)

6. Who’s a Candidate?

✅ BMI ≥ 30, or BMI ≥ 27 with hypertension, dyslipidemia, OSA, NAFLD, or PCOS
✅ Failed prior lifestyle-only attempts
🚫 Personal or family history of medullary thyroid cancer or MEN 2
🚫 Active pancreatitis

7. The GitelCare GLP-1 Protocol

Comprehensive Baseline – 90-min visit with body-comp InBody scans, metabolic labs, and ultrasounds.
Medication Selection – Algorithm weighs GI tolerance, CV risk, insurance coverage.
Lifestyle Stack – RD-guided high-protein diet, resistance training, sleep tracking.
Quarterly Optimization – Review labs, adjust dose, add adjuncts (e.g., Ω-3, berberine).
Maintenance Phase – Transition to lowest effective dose after target fat-mass goal met.

Average member hits -18 % body weight at 12 months with <5 % regain at 24 months.